

ROBERTO DE MIRO

ECPC LEGAL NETWORK FOR CANCER PATIENTS MEETING



Roberto De Miro  
F.A.V.O. Italy

Born in Rome, Italy on Feb 8th , 1964 I learned from my father who was a High Officer in the Italian Air Force how to concentrate my efforts to achieve a target and from my mother who is a retired English teacher the curiosity for any foreign or different culture.

After high school (humanities), in the years 1989-1994 I visited Santiago de Compostela in a 100 Miles walk, graduated magna cum laude in Law, specialised in Roman and Comparative Law, was admitted to the Bar (then in 2006 at the High Courts) and appointed teacher of Law and Economics in State High School.

Married and proud father of a 10yours old daughter. As a Lawyer, but also for my experience of long term (over 23 Years) carer to a family member who is a cancer patient, I had the opportunity to concentrate on the psychosocial needs of cancer and other disability patients, to revenue existing laws on the matter (especially Labour / Bank and Insurance Law) and even to participate to legal drafting of Labour reforms.

I took part in the drafting of the Statutes of the European Cancer Patients Coalition (ECPC) prior to the times when this entity moved from London to the NL. Also, I had a responsibility in drafting the Statutes of the Italian Federation of Volunteer-based Cancer Organisations (FAVO) which is the representative Forum of over 500 associations of cancer volunteers in Italy. Former Member of the Working Group on the Rights of Cancer Patients within the European Cancer League (ECL), when the Oslo Declaration on the subject was adopted, I was in Warsaw for ECPC when in November 2005 the Warsaw Declaration was adopted by leading patient groups at the Second Congress of Cancer Patients Organizations from Central and Eastern Europe.

My commitment in advocacy for cancer patients is to demonstrate that the best interest of the patients and their carers resides in cooperation among the stakeholders: Industry / Public welfare / Families / Health professionals / Banks and Insurers / Employers. Law reforms are needed and critical to the issue, but I also deem necessary to avoid any old-fashioned attitude of not necessary opposition – but for the cases in which a right need to be affirmed, of course.

JOHN-FLETCHER SMYTH

COMMUNICATING WITH PEOPLE AFFECTED BY CANCER



John-Fletcher Smyth  
University of Edinburgh UK

After graduating from Cambridge University in 1970, John Smyth trained in medical oncology at St Bartholomew’s Hospital and the Royal Marsden, London, the NCI and the University of Chicago, USA. In 1978 he was appointed to the first Chair of Medical Oncology in Edinburgh. Over the subsequent 30 years he has developed multidisciplinary oncology to create the Edinburgh Cancer Research Centre that combines laboratory and clinical research with teaching and training, serving a population of 2 million people. Since January 2009 he has served as Emeritus Professor and Assistant Principal for Cancer Research Development.

His research expertise is in experimental therapeutics from drug design through all phases of pre-clinical evaluation to clinical trials, with his major research interest in the development of new anti-cancer drugs. He has served on the UK Committee on Safety of Medicines, the EMEA Scientific Advisory Group for Oncology and Chaired the Expert Advisory Group for Oncology & Haematology for the Commission on Human Medicines. He has had a particular interest in Palliative Medicine and was instrumental in securing the funding and subsequent establishment of the first Chair

of Palliative Care within the University of Edinburgh. His current interests are focused on the affordability of cancer related healthcare.

He has published over 300 papers and been involved in 47 books and chapters, most recently in 2013 when he published a book entitled “Communicating with Cancer Patients”. He was also Editor-in-Chief of the European Journal of Cancer, UK from 2001 - 2010. He is a fellow of the Royal College of Physicians of Edinburgh and London, and fellow of the Royal Society of Edinburgh, and is a past-president of the European Society of Medical Oncology and the Federation of European Cancer Societies.



Katie Hamilton  
Costello Medical UK

KATIE HAMILTON

HTA ONLINE EDUCATION MODULE

Katie Hamilton – Consultant at Costello Medical

Costello Medical provides scientific support to the healthcare sector in the analysis, interpretation and communication of clinical and health economic data. As a Consultant in the Medical Affairs Division, Katie specialises in the development of training materials and the provision of advisory board and congress support. She has a broad range of experience in the therapy areas of immunology, oncology, neurology, mental health and infectious diseases.

Katie is very interested in the various ways that industry and patients can work together to improve outcomes. She has presented several pieces of original research at international conferences and has completed the Postgraduate Certificate in Health Economics for Health Care Professionals at the University of York. She Before joining Costello Medical, Katie graduated from the University of Cambridge in June 2013 with a BA in Biological Natural Sciences.



Irina Cleemput  
Belgian Health Care Knowledge Centre

IRINA CLEEMPUT

HTA AND REIMBURSEMENT

Irina Cleemput is Senior Health Economist at the Belgian Health Care Knowledge Centre (KCE) since 2004. She obtained her PhD in Public Health at the K.U.Leuven (Belgium) in 2003, after which she specialized in Health Technology Assessment (HTA) and Health Services Research at KCE. She was a Director of the International Network of Health Technology Assessment Agencies (INAHTA) from 2009 to 2015, professor at the University of Hasselt until 2014 and co-editor of Health Policy.

Irina is actively involved in the activities of EUnetHTA relating to methodology for HTA. Irina developed a specific interest in the relative value of health economic evaluations for policy making purposes in Belgium and other countries. She performed research on implicit value judgments in drug reimbursement decision-making processes.

Together with a team of experts at KCE and in collaboration with the Belgian National Institute for Health and Disability Insurance (RIZIV/INAMI), Irina Cleemput developed Belgian guidelines for pharmacoeconomic evaluations. Her current domains of work relate to patient involvement in healthcare policy, the identification of patient needs and the role of patient-reported outcome and experience measures in health policy.



*Ioana Siska*  
European Commission, DG SANTE

IOANA SISKA

OVERVIEW OF THE EUROPEAN COMMISSION'S HTA PROPOSAL

Ioana Siska is a medical doctor by training, with a PhD in medicine and experience in teaching human physiology and immunology. She is Policy Officer in the Health Technology Assessment team at the European Commission in DG SANTE, Unit "Medical products: quality, safety and innovation". The team is responsible for developing an EU initiative on Strengthening EU cooperation on HTA, it is providing the Secretariat to the HTA Network, set up by Article 15 of the Directive 2011/24/EU on "the application of patients' rights in cross-border healthcare", and oversees the activities of the Joint Action EUnetHTA.

Ioana joined the European Commission in 2006 in the Health Directorate of DG Research and worked as Scientific Officer in the Genomics and Systems Biology Unit, where she managed several EU funded projects in the area of bio-banking and population genetics.

Ioana joined DG SANTE in 2010 as Policy Officer responsible for the EU legislation concerning tissue and cell transplantation and in 2016 became a member of the HTA team.

IVANA CATTANEO

HTA: HOW TO CREATE A WIN-WIN SOLUTION



*Ivana Cattaneo*  
Vice-Chair EFPIA Oncology Steering Group

Ivana Cattaneo

Senior professional with over twenty-year experience in management, leadership and organizational development, at global level and with major multinational companies.

Current role:

- Public Affairs Director Oncology Europe, Novartis

Responsible for Oncology Public Affairs at European level, leading international projects and managing institutional relations.

Previous roles:

Novartis Oncology

- Director, Market Access and External Affairs Europe, Rare Disease Unit
- Director, Academy Market Access Excellence Europe

Collaborations and projects:

- Tutor at EUPATI for access and health economics modules
- Project leader at AGORA (Advisory Group On Reimbursement and Access) a think tank to facilitate and improve European patients access to innovative solutions
- Founding member of POLE (Programme for Oncology Leadership in Europe) together with ESO (European School of Oncology) and SDA Bocconi School of Management
- Organizer of the first "Patients roundtable at ISPOR", now a multi-stakeholder' platform
- Creation of Atlas of Medicine, app to give compounds access info to patient's organizations across Europe – project leveraged by ESMO
- Vice-Chair of the EFPIA Oncology Platform

Education

- Degree in foreign literature
- Master in management
- Currently completing the MSc in Health Economics

Reachable at: [ivana.cattaneo@novartis.com](mailto:ivana.cattaneo@novartis.com) .

LEIF HAKANSSON

IMMUNO-ONCOLOGY THERAPIES & MOLECULAR TESTING



Leif Hakansson  
CDDF Board of Directors

Leif Håkansson is Associate Professor of Anatomy at the University of Lund, Sweden, and Consultant in Oncology and Head of the Division of Clinical Tumor Immunology at the University Hospital in Linköping, Sweden. His research includes immune parameters of importance for response, monitoring and optimization of immunotherapy and biochemotherapy in various types of cancer, e.g. renal cell carcinoma, malignant melanoma and colorectal cancer.

NICOLA NORMANNO



Nicola Normanno  
Istituto Nazionale per lo Studio e la Cura dei Tumori

Dr Nicola Normanno was born in Ottaviano (Italy) in 1964 and graduated cum laude in Medicine and Surgery in 1988. He worked as postdoctoral fellow in the National Cancer Institute of Bethesda (USA), then he specialized in Medical Oncology and later in Hematology. In 2004 he won the “Annals of Oncology Prize for Translational Research” and in 2005 he became Adjunct Associate Professor at the Temple University of Philadelphia. From 2005 he has been appointed as Director of the Cell Biology and Biotherapy Unit of INT Fondazione “G. Pascale” and from 2006 he is the Chairman of the Research Department of the same institute.

Dr. Normanno leads a research group involved in both pre-clinical and clinical studies, with particular regard to the identification of biomarkers associated with sensitivity/resistance to target-based agents in clinical development. Dr. Normanno’s group has been one of the first to use next generation sequencing (NGS)-based techniques in clinical trials. His group has a relevant expertise in liquid biopsy. Dr. Normanno is also involved in clinical diagnostics and in the organization of national and international external quality assessment (EQA) schemes in molecular pathology.

Dr Normanno is a member of many national and international cancer research associations (AACR, GOIM, AIOT, ESMO, AIOM, SIC, FONICAP). He is President Elect of the Italian Society of Cancerology (SIC). Dr. Normanno is author of more than 200 publications in international journals and he is a reviewer for many peer reviewed journals.



Tim Brown  
Fight Bladder UK

TIM BROWN  
PERSONAL TESTIMONIES FROM CANCER CARERS

Tim Brown, 47, married to Anita, who has small cell bladder cancer. Lives with their son, Ashleigh, Sherlock, our chocolate Labrador, 3 cats, Ollie, Fuggers & Moma Cat & Barney the bunny. They all live in Hampshire, U.K. Tim enjoys riding his motorbike, drinking beer and watching football.

CLAIRE CHAMPEIX  
EUROCARERS CANCER CARERS TOOLKIT, PRODUCED IN  
COLLABORATION WITH ECPC



Claire Champeix  
Policy Officer at Eurocarers

Claire Champeix, Policy Officer

Claire has an extensive experience of policy work, research and project coordination in the social field at the local and European levels. She has worked with social NGOs at the European level for more than 13 years, and contributed to efficient lobbying and awareness raising strategies aimed at developing social cohesion.

In her previous job, she coordinated a project gathering NGOs, local authorities, services providers, Foundations, as well as international organisations aiming at fostering the transition from institutional to community-based care for children and dependent people in the European Union. Previously, she has been active to promote the rights and the participation of people experiencing poverty, discrimination and social exclusion. She has also been working with local authorities for 7 years. Claire studied Political Sciences and Sociology.





*Françoise Meunier*  
 European Organisation for Research  
 and Treatment of Cancer- EORTC

## FRANCOISE MEUNIER

EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF  
 CANCER- EORTC

Françoise Meunier received her medical degree from the Université Libre de Bruxelles (ULB) (magna cum laude) and completed a research fellowship at Memorial Sloan-Kettering Cancer Center (New York, 1977-1978, Fulbright award). She holds a Master's Degree in Medical Oncology (1976) and Internal Medicine (1979), and a PhD (1985) at the ULB. She is certified as Pharmaceutical Medicine specialist (Faculty of Pharmaceutical Medicine, UK) as well as in Belgium and she is a Fellow of the Royal College of Physicians (UK).

Françoise Meunier served as EORTC Director General from 1991 through 2015 and oversaw the growth of the EORTC into an international world class cancer clinical research infrastructure. Upon stepping down as Director General in 2015, Françoise remains active as EORTC Director Special Projects where she is a driving force behind activities such as EORTC cancer survivorship initiatives. She also lends her valuable experience to fundraising projects and sits on the board of the EORTC Cancer Research Fund.

Prior to joining the EORTC in 1991, Françoise Meunier was Head of Infectious Diseases Department at Institute Jules Bordet in Brussels, Belgium and her personal area of research included the management of infections in patients with Cancer and mainly Invasive Fungal Infections. She has over 150 peer-reviewed published articles.

Françoise Meunier was awarded the Belgian Laureate "Prix Femmes d'Europe 2004-2005". She is a member of the Belgian Royal Academy of Medicine since 2006. In 2007, she was conferred the title of Baroness by His Majesty, The King Albert II of Belgium.

She received in 2009, the Pezcoller Foundation award as a recognition for her contribution to oncology. Since 2011, she is a Fellow of the European Academy of Cancer Sciences.

From 2012 to 2016, she was member of the IMI (Innovative Medicine Initiative) Scientific Committee.

In 2013, she received the ECCO Life time achievement award. She was awarded a Ben de Pauw Medal for her dedication to Medical Mycology and her contribution to the EORTC Infectious Diseases Group.

From 2013 - 2016, she acted as Chair of the Accreditation Council of Oncology in Europe (ACOE). Since 2014, she is board member of "Centre Scientifique de Monaco".

Since 2015, she is Vice-President of FEAM (Federation of European Academies of Medicine) and board member of Alliance for Biomedical Research in Europe. On 3 July 2015, she was admitted to the degree of Doctor of Medical Science (Honoris Causa) by the Queen's University of Belfast, Northern Ireland, UK.

Since 2017, she is member of the Scientific Panel for Health (SPH) of the European Commission.